At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
D-serinedrug
Likely dose
D-serine 60 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
D-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot
Nathan Kline Institute for Psychiatric Research·interventional·Posted Jun 5, 2014·Updated Oct 8, 2020
In Brief
A Phase 2 clinical trial evaluating D-serine for Schizophrenia. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The investigators will test the effects of 3 days of D-serine (DSR) on auditory plasticity in a sensory based remediation (SBR) paradigm
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedJun 5, 2014
Enrollment StartAug 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.1 years ago
Interventions
D-serinedrug
D-serine 60 mg/kg